Market Research Logo

US Market Report for Transcatheter Embolization Particles - MedCore

Transcatheter embolization is the practice of introducing material to within the vasculature to induce blood flow occlusions. Transcatheter embolization is effective for treating vessel malformations such as aneurysms, fistulae and bleeding. If left untreated, some of these arteriovenous malformations can ultimately lead to strokes. In addition, transcatheter embolization is an effective therapy for blocking blood flow to tumors or organs, thus starving the target tissues. Specialized particles, such as drug-coated and radiolabeled beads, are used for the targeted delivery of drugs and for radiation therapy, respectively.


EXECUTIVE SUMMARY FOR COMPLETE REPORT SUITE
1.1 MARKET OVERVIEW
1.2 COMPETITIVE LANDSCAPE
1.3 MARKET TRENDS
1.4 KEY MARKET DEVELOPMENTS
1.5 INCIDENCE RATES INCLUDED
1.6 PROCEDURE NUMBERS
1.7 MARKETS INCLUDED
1.8 KEY REPORT UPDATES
1.9 VERSION HISTORY
RESEARCH METHODOLOGY
2.1 RESEARCH SCOPE
2.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
CANCER INCIDENCE RATES
3.1 INTRODUCTION
3.2 CANCER BY TYPE
3.2.1 Genital Cancer
3.2.2 Digestive Cancer
3.2.3 Respiratory Cancer
3.2.4 Breast Cancer
3.2.5 Urinary Cancer
3.2.6 Skin Cancer
3.2.7 Lymphoma
3.2.8 Endocrine System Cancer
3.2.9 Leukemia
3.2.10 Oral Cavity/Larynx
3.2.11 Myeloma
3.2.12 Brain/Other Nervous System
3.2.13 Soft Tissue (Non-Heart)
3.2.14 Bones and Joints
3.2.15 Eye and Orbit
TRANSCATHETER EMBOLIZATION PARTICLE MARKET
4.1 INTRODUCTION
4.1.1 Polyvinyl Alcohol Particles
4.1.2 Microspheres
4.1.3 Drug-eluting Particles
4.1.4 Radioactive Particles
4.1.5 General Information
4.2 MARKET OVERVIEW
4.3 MARKET ANALYSIS AND FORECAST
4.3.1 PVA Particle Market
4.3.2 Microsphere Market
4.3.3 Drug-Eluting Particle Market
4.3.4 Radioactive Particle Market
4.4 DRIVERS AND LIMITERS
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 COMPETITIVE ANALYSIS
ABBREVIATIONS
List of Chart
Chart 1 1: Interventional Oncology Device Market by Segment, U.S., 2012 – 2022 (US$M) 2
Chart 1 2: Interventional Oncology Device Market Overview, U.S., 2015 & 2022 2
Chart 3 1: Male Incidence, Genital Cancer, U.S., 2014 32
Chart 3 2: Male Deaths, Genital Cancer, U.S., 2014 32
Chart 3 3: Female Incidence, Genital Cancer, U.S., 2014 33
Chart 3 4: Female Deaths, Genital Cancer, U.S., 2014 33
Chart 3 5: Male Incidence, Digestive Cancer, U.S., 2014 35
Chart 3 6: Male Deaths, Digestive Cancer, U.S., 2014 35
Chart 3 7: Female Incidence, Digestive Cancer, U.S., 2014 36
Chart 3 8: Female Deaths, Digestive Cancer, U.S., 2014 36
Chart 3 9: Male Incidence, Respiratory Cancer, U.S., 2014 38
Chart 3 10: Male Deaths, Respiratory Cancer, U.S., 2014 38
Chart 3 11: Female Incidence, Respiratory Cancer, U.S., 2014 39
Chart 3 12: Female Deaths, Respiratory Cancer, U.S., 2014 39
Chart 3 13: Incidence by Gender, Breast Cancer, U.S., 2014 41
Chart 3 14: Deaths by Gender, Breast Cancer, U.S., 2014 41
Chart 3 15: Male Incidence, Urinary Cancer, U.S., 2014 43
Chart 3 16: Male Deaths, Urinary Cancer, U.S., 2014 43
Chart 3 17: Female Incidence, Urinary Cancer, U.S., 2014 44
Chart 3 18: Female Deaths, Urinary Cancer, U.S., 2014 44
Chart 3 19: Male Incidence, Skin Cancer, U.S., 2014 46
Chart 3 20: Male Deaths, Skin Cancer, U.S., 2014 46
Chart 3 21: Female Incidence, Skin Cancer, U.S., 2014 47
Chart 3 22: Female Deaths, Skin Cancer, U.S., 2014 47
Chart 3 23: Male Incidence, Lymphoma Cancer, U.S., 2014 49
Chart 3 24: Male Deaths, Lymphoma Cancer, U.S., 2014 49
Chart 3 25: Female Incidence, Lymphoma Cancer, U.S., 2014 50
Chart 3 26: Female Deaths, Lymphoma Cancer, U.S., 2014 50
Chart 3 27: Male Incidence, Endocrine Cancer, U.S., 2014 52
Chart 3 28: Male Deaths, Endocrine Cancer, U.S., 2014 52
Chart 3 29: Female Incidence, Endocrine Cancer, U.S., 2014 53
Chart 3 30: Female Deaths, Endocrine Cancer, U.S., 2014 53
Chart 3 31: Male Incidence, Leukemia Cancer, U.S., 2014 55
Chart 3 32: Male Deaths, Leukemia Cancer, U.S., 2014 55
Chart 3 33: Female Incidence, Leukemia Cancer, U.S., 2014 56
Chart 3 34: Female Deaths, Leukemia Cancer, U.S., 2014 56
Chart 3 35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2014 58
Chart 3 36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2014 58
Chart 3 37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2014 59
Chart 3 38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2014 59
Chart 3 39: Incidence by Gender, Myeloma Cancer, U.S., 2014 61
Chart 3 40: Deaths by Gender, Myeloma Cancer, U.S., 2014 61
Chart 3 41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2014 63
Chart 3 42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2014 63
Chart 3 43: Incidence by Gender, Soft Tissue Cancer, U.S., 2014 65
Chart 3 44: Deaths by Gender, Soft Tissue Cancer, U.S., 2014 65
Chart 3 45: Incidence by Gender, Bone and Joint Cancers, U.S., 2014 67
Chart 3 46: Deaths by Gender, Bone and Joint Cancers, U.S., 2014 67
Chart 3 47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2014 69
Chart 3 48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2014 69
Chart 4 1: Transcatheter Embolization Particle Market by Segment, U.S., 2012 – 2022 75
Chart 4 2: Transcatheter Embolization Particle Market Breakdown, U.S., 2015 76
Chart 4 3: Transcatheter Embolization Particle Market Breakdown, U.S., 2022 76
Chart 4 4: PVA Particle Market, U.S., 2012 – 2022 78
Chart 4 5: Microsphere Market, U.S., 2012 – 2022 80
Chart 4 6: Drug-Eluting Particle Market, U.S., 2012 – 2022 82
Chart 4 7: Radioactive Particle Market, U.S., 2012 – 2022 84
Chart 4 8: Leading Competitors, Transcatheter Embolization Particle Market, 2015 90
List of Figures
Figure 1 1: Interventional Oncology Device Market Share Ranking by Segment, U.S., 2015 3
Figure 1 2: Companies Research in this Report Suite, U.S., 2015 4
Figure 1 3: Factors Impacting the Interventional Oncology Device Market by Segment, U.S. 5
Figure 1 4: Recent Events in the Interventional Oncology Device Market, U.S., 2012 – 2015 (1 of 3) 6
Figure 1 5: Recent Events in the Interventional Oncology Device Market, U.S., 2012 – 2015 (2 of 3) 7
Figure 1 6: Recent Events in the Interventional Oncology Device Market, U.S., 2012 – 2015 (3 of 3) 8
Figure 1 7: Cancer Incidence Rates Covered, U.S., 2015 (1 of 2) 9
Figure 1 8: Cancer Incidence Rates Covered, U.S., 2015 (2 of 2) 10
Figure 1 9: Interventional Oncology Procedures Covered, U.S., 2015 11
Figure 1 10: Procedural Codes, U.S., 2015 12
Figure 1 11: Interventional Oncology Device Markets Covered, U.S., 2012 – 2022 (1 of 2) 13
Figure 1 12: Interventional Oncology Device Markets Covered, U.S., 2012 – 2022 (2 of 2) 14
Figure 1 13: Key Report Updates, U.S., 2016 15
Figure 1 14: Version History 15
Figure 3 1: Genital Cancer Statistics by Type and Gender, U.S., 2014 31
Figure 3 2: Digestive Cancer Statistics by Type and Gender, U.S., 2014 34
Figure 3 3: Respiratory Cancer Statistics by Type and Gender, U.S., 2014 37
Figure 3 4: Breast Cancer Statistics by Type and Gender, U.S., 2014 40
Figure 3 5: Urinary Cancer Statistics by Type and Gender, U.S., 2014 42
Figure 3 6: Skin Cancer Statistics by Type and Gender, U.S., 2014 45
Figure 3 7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2014 48
Figure 3 8: Endocrine Cancer Statistics by Type and Gender, U.S., 2014 51
Figure 3 9: Leukemia Cancer Statistics by Type and Gender, U.S., 2014 54
Figure 3 10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2014 57
Figure 3 11: Myeloma Cancer Statistics by Type and Gender, U.S., 2014 60
Figure 3 12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2014 62
Figure 3 13: Soft Tissue (Non-Heart) Cancer Statistics by Type and Gender, U.S., 2014 64
Figure 3 14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2014 66
Figure 3 15: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2014 68
Figure 4 1: Transcatheter Embolization Device Characteristics 73
Figure 4 2: Transcatheter Embolization Particle Market by Segment, U.S., 2012 – 2022 (US$M) 75
Figure 4 3: PVA Particle Market, U.S., 2012 – 2022 77
Figure 4 4: Microsphere Market, U.S., 2012 – 2022 79
Figure 4 5: Drug-Eluting Particle Market, U.S., 2012 – 2022 81
Figure 4 6: Radioactive Particle Market, U.S., 2012 – 2022 83
Figure 4 7: Drivers and Limiters, Embolization Particle Market, U.S., 2015 87
Figure 4 8: Leading Competitors, Transcatheter Embolization Particle Market, 2015 89

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report